Literature DB >> 6336980

Gastric pseudolymphoma. Its three subtypes and relation to lymphoma.

J J Brooks, H T Enterline.   

Abstract

Three separate histologic types of gastric pseudolymphoma (GPL) are described: (1) the common "inflammatory" type usually accompanied by ulceration and extensive fibrosis; (2) the entity known as "nodular lymphoid hyperplasia," which was associated with multiple intestinal lesions; and (3) the third reported case of angiofollicular lymphoid hyperplasia of the stomach (one with nodal involvement). Criteria for the common type were developed and, in general, confirm previous studies. However, the importance of evaluating nuclear cytology and mitotic rate are stressed. Organ infiltration by chronic lymphocytic leukemia should be excluded by the absence of an absolute peripheral lymphocytosis. In addition to the ten cases presented, the literature on 175 previous cases is summarized. GPL is estimated to account for 10-15% of all gastric lymphoid tumors. In comparison to gastric lymphoma, GPL is usually smaller in size and occurs a decade earlier on the average. Since an associated focal lymphoma was documented in an additional five cases, this study proposes that pseudolymphoma be considered a precursor lesion with malignant potential. Extensive pathologic sampling and total surgical excision are recommended.

Entities:  

Mesh:

Year:  1983        PMID: 6336980     DOI: 10.1002/1097-0142(19830201)51:3<476::aid-cncr2820510320>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Pseudolymphoma (reactive lymphoid hyperplasia) of the liver: A clinical challenge.

Authors:  Yong Kyong Kwon; Reena C Jha; Kambiz Etesami; Thomas M Fishbein; Metin Ozdemirli; Chirag S Desai
Journal:  World J Hepatol       Date:  2015-11-18

2.  Gastric pseudolymphoma. Not necessarily a benign lesion.

Authors:  J F Sweeney; C Muus; P P McKeown; A S Rosemurgy
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

3.  Gastric "pseudolymphoma" with restricted light chain expression in a patient with obscure gastrointestinal blood loss.

Authors:  H Schulman; J Sickel; M S Kleinman; J T Adams
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

4.  Primary gastric non-Hodgkin's lymphomas in Japan.

Authors:  N Mohri
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

5.  Malignant lymphoma of the gastrointestinal tract and mesentery. A clinico-pathologic study of the significance of histologic classification. NHL Study Group of the Comprehensive Cancer Center West.

Authors:  J H van Krieken; R Otter; J Hermans; K van Groningen; P J Spaander; M M van de Sandt; J F Keuning; P M Kluin
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

6.  Pseudolymphoma of the jejunum.

Authors:  H Gudjonsson; M Jones; E L Krawitt; M D Kaye
Journal:  Dig Dis Sci       Date:  1987-11       Impact factor: 3.199

7.  An operative case of hepatic pseudolymphoma difficult to differentiate from primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Authors:  Michihiro Hayashi; Noboru Yonetani; Fumitoshi Hirokawa; Mitsuhiro Asakuma; Katsuhiko Miyaji; Atsushi Takeshita; Kazuhiro Yamamoto; Hironori Haga; Takayuki Takubo; Nobuhiko Tanigawa
Journal:  World J Surg Oncol       Date:  2011-01-13       Impact factor: 2.754

8.  Gastric pseudolymphoma. A challenging clinical problem.

Authors:  R K Orr; J R Lininger; W Lawrence
Journal:  Ann Surg       Date:  1984-08       Impact factor: 12.969

Review 9.  Pseudolymphoma of the liver associated with primary biliary cirrhosis: a case report and review of literature.

Authors:  Toshihide Okada; Hiroshi Mibayashi; Kenkei Hasatani; Yoshiaki Hayashi; Shigetsugu Tsuji; Yoshibumi Kaneko; Masashi Yoshimitsu; Takashi Tani; Yoh Zen; Masakazu Yamagishi
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

Review 10.  Endoscopic and histologic resolution of gastric pseudolymphoma (reactive lymphoid hyperplasia) following treatment with bismuth and oral antibiotics.

Authors:  A P Weston; D R Campbell; D H McGregor; R Cherian
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.